Replies to post #278751 on Anavex Life Sciences Corp (AVXL)

[rayovacAAA]

EXPECT AVXL TO AQUIRE EISAI AND COGSTATE BY THE END OF THIS FISCAL QUARTER!!!!!!!!!!!!!!!!!

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
JAPAN CORPORATE NEWS 2:52 AM ET 10/26/2020

GOOD LUCK AND GOD BLESS!!!!!!!!!!!!!!!!

[Boopka]

tradepete, very interesting post. TY. Were terms mentioned? Dollar amounts or shares? Eisai tests and Anavex treats. Another interesting possibility.

[tredenwater2]

Vn traderpete great find. Esaly moveing one step ahead with self dianostic tools for the brain. Do you know if we worked with Cogstate down in AU?

[plexrec]

Eisai-"delivering innovative products to address unmet medical needs,"--still think Anavex and Eisai would make up a great team--if they partnered in some way--they have so much in common !!! Harold--are you around ????

[XenaLives]

Google "Anavex Cogstate", get this:

first page only

About 1,190 results (0.33 seconds)

Corporate Presentation - Anavex Life Scienceswww.anavex.com › Anavex-Presentation-October-2019
PDF
Identification (IDN) in Cogstate battery assessed in ANAVEX®2-73 Ph2a AD Study comparable to CDR Continuity of Attention (choice reaction time paradigm).

FDA granted Orphan status to ANAVEX™ 2-73 for Rett ...www.anavex.com › my_uploads › Anavex-September-...
PDF
Cogstate's test battery for Alzheimer's disease measures the following core ... Cogstate's computerized battery includes tests that have been utilized previously in.

Corporate Presentation - Anavex Life Scienceswww.anavex.com › Anavex-Presentation-March-2019-1
PDF
Mar 1, 2019 — Identification (IDN) in Cogstate battery assessed in ANAVEX®2-73 ... Cogstate IDN: ANAVEX®2-73 Ph2a AD Patients Improve within Weeks vs.

Anavex Announces Positive Primary and Secondary ...www.anavex.com › anavex-announces-positive-primar...
Nov 9, 2015 — Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people's ability to store and use information ...

Anavex Life Sciences Announces Achievement of Enrollment ...www.anavex.com › anavex-life-sciences-announces-ac...
Jan 27, 2020 — ... dependent improvement in exploratory endpoints of cognition (ERP/EEG, Cogstate, Mini-Mental State Examination – MMSE) within 5 weeks.
You've visited this page 2 times. Last visit: 9/1/20

Anavex Life Sciences Announces 12-Month Data of ANAVEX ...www.anavex.com › anavex-life-sciences-announces-12...
Dec 8, 2016 — Published AD studies confirmed substantial declines of cognitive (MMSE) and functional (ADCS-ADL) measures as well as Cogstate and ...

Anavex Presents 31-Week Efficacy Data from Phase 2a Study ...www.anavex.com › anavex-presents-31-week-efficacy-...
Jul 27, 2016 — The 31-week data also validates the earlier observation of improvements on tasks within the Cogstate battery. The specificity and consistency ...

Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase ...www.anavex.com › wp-content › uploads › Safety-and...
PDF
converging and consistent response for all measurements (MMSE,. ADCS-ADL, Cogstate, EEG/ERP) currently throughout 31 weeks (7 months) of ANAVEX 2-73 ...
by S Macfarlane · ?Cited by 3 · ?Related articles

Anavex Life Sciences Presents New Three-Year, Longitudinal ...www.anavex.com › anavex-life-sciences-presents-new-t...
Oct 26, 2018 — ... well as Cogstate test battery and biomarker EEG/ERP. About ANAVEX®2-73-003 Phase 2a Clinical Study (ClinicalTrials.gov NCT02756858).

Higher Concentration ANAVEX 2-73 Displays Positive Effect ...www.neurologylive.com › view › higher-concentration...
Oct 26, 2018 — Anavex Life Sciences today announced findings from the phase 2a ... of ADCS-ADL, as well as Cogstate test battery and biomarker EEG/ERP.

[nidan7500]

Excellent news. We cannot mange something we cannot measure. Get ready to say BYE-BYE to the 5 year CNS disease trial routine...finally.

About Eisai Co., Ltd.(ESALF)

Eisai Co., Ltd.(ESALF) defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For further information on Eisai Co., Ltd.(ESALF), please visit https://www.eisai.com

About Cogstate Ltd.

Cogstate Ltd. is a neuroscience technology company headquartered in Melbourne, Victoria, Australia and New Haven, Connecticut, USA, focused on optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Since 1999, Cogstate technologies have provided rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains. The company's clinical trials solutions include quality assurance services for clinical outcome assessments that combine electronic data capture, innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Notwithstanding this agreement, Cogstate will continue to independently offer its technology and services to the clinical trials market.

For further information on Cogstate, please visit www.cogstate.com.

Eisai Co., Ltd.(ESALF)
Public Relations Department
TEL : [phone]

Cogstate, Ltd.
Rachel Colite: [e-mail]
Natalie Hasapaki: [e-mail]